Ridgeline, a Versant Ventures Discovery Engine, was founded in early 2017 to create and operate Versant-financed innovative biotech companies in Basel, Switzerland. In its first year Ridgeline assembled an international team of 20 highly experienced drug discovery professionals and built and operated three new companies, including Black Diamond, Bright Peak and Monte Rosa.
Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm’s emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $3.2 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 75 Versant companies have achieved successful acquisitions or IPOs. Versant is currently investing out of its seventh fund, Versant Venture Capital VII, a $600 million global biotech fund closed in December 2018. In parallel the firm co-invests out of its Canadian strategic fund Versant Voyageurs I and its later-stage biotech opportunity fund Versant Vantage I. For more information, please visit www.versantventures.com.
We partner with entrepreneurs and leading academics across Europe to access breakthrough transformational science that serves as the foundation of our company creation efforts.
Together with our academic founders, our international team of accomplished industry R&D veterans drives research to create novel platforms and high-quality therapeutic candidates.
Our international team has deep investment, research and operating experience that enables an efficient, hands-on approach to company building and value creation.
is VP of Preclinical Development at Ridgeline.
is a Principal at Versant Ventures and acting CBO at Ridgeline.